On August 19, AstraZeneca PLC rose 3.1% in regular trading, trading at $165.2/share, with turnover of $127 million. The move came amid a cluster of pipeline catalysts and broad-based pharma sector strength.

On the news front, AstraZeneca and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 trial achieved positive top-line results, with Enhertu as monotherapy demonstrating statistically significant and clinically meaningful improvement in PFS versus standard of care as first-line treatment for HER2-mutant non-small cell lung cancer. Enhertu is the first and only HER2-targeted ADC to defeat standard therapy in this indication in a Phase III setting. Separately, the global Phase III SAFFRON study of Tagrisso combined with savolitinib also met dual PFS and OS primary endpoints.

Additionally, tezepelumab was officially launched in China for two approved indications — maintenance treatment of severe asthma and chronic rhinosinusitis with nasal polyps — following approvals earlier this year based on positive Phase III DIRECTION and WAYPOINT study results. Meanwhile, the broader Pharmacy sector rallied, with Merck up 11.47%, Eli Lilly up 5.26%, Pfizer up 4.17%, and Novo-Nordisk up 3.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)